Woodcliff Lake-based Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd., announced Wednesday it has appointed Adriana Herrera as senior vice president, Americas commercial oncology.
In this role, Herrera will be responsible for developing and implementing the company’s commercial strategy to help grow its oncology business in the Americas region. She will also head the oncology commercial organization.
“We welcome Adriana to our executive leadership team to steer our Oncology business through its next exciting phase of growth,” Paul Hawthorne, executive vice president and chief commercial cfficer of Eisai Inc., said. “She has excelled in launching oncology brands, developing disease awareness initiatives, creating market access strategies, and leading highly successful teams throughout her career. Her experiences, enthusiasm and personal commitment to patients align well with Eisai’s goal of Breaking Through to address some of society’s most difficult healthcare challenges.”
Prior to Eisai, Herrera was at Novartis Oncology for 12 years, most recently as vice president, global disease lead lung cancer. Before that, she held marketing, sales and operations roles of increasing responsibility at Novartis and Bristol Myers Squibb.
“Eisai continues to work tirelessly to improve outcomes for oncology patients through its innovative products, unique pipeline, and focus on immuno-modulation,” Herrera said. “The company’s commitment to its human health care (hhc) mission and patient-centricity strongly resonate with my personal values. I am excited to join Eisai and make a difference for patients and their families.”
